Date: 2016-01-11
Type of information: Nomination
Compound:
Company: Serodus (Norway)
Therapeutic area: Metabolic diseases
Type agreement: nomination
Action mechanism:
Disease: type 2 diabetes
Details: * On January 11, 2016, Serodus announced the formation of a new Scientific Advisory Board for the development program in type 2 diabetes (SER140). The appointed scientific advisors for the development program are: Prof. Richard E Pratley, MD, Florida Hospital Diabetes Institute, FL, USA. Dr. Pratley is an internationally recognized expert in diabetes and is board certified in internal medicine. He received his medical degree from Wayne State University in Detroit, and completed fellowships in geriatric medicine and gerontology at the University of Michigan, John Hopkins University, and the National Institute on Aging. As a member of the American Diabetes Association, the European Association for the Study of Diabetes and The Obesity Society, Dr. Pratley continues his active involvement in the professional community. Professor Thomas Mandrup-Poulsen, MD, DMSc, Copenhagen University Hospital, Denmark. Thomas Mandrup-Poulsen is a physician scientist, specialist in internal medicine and endocrinology. He is a pioneer in the field of immuno-metabolism with the discovery that inflammatory cytokines impair the function and viability of pancreatic islet b-cells, for which he was awarded the 1994 Minkowski Prize of the EASD.
Financial terms:
Latest news:
